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Reduced toxicity and ease of modiﬁcation make gold nanoparticles (GNPs) suitable for targeted delivery,
bioimaging and theranostics by conjugating cell-penetrating peptides (CPPs). This study presents the
biodistribution and enhanced intracellular uptake of GNPs functionalized with VG-21, a CPP derived from
vesicular stomatitis virus glycoprotein (G). Cell penetrating efﬁciency of VG-21 was demonstrated using
CellPPD web server, conjugated to GNPs and were characterized using, UV-visible and FTIR spectroscopy,
transmission electron microscopy, dynamic light scattering and zeta potential. Uptake of VG-21 func-
tionalized GNPs (fGNPs) was tested in eukaryotic cell lines, HEp-2, HeLa, Vero and Cos-7, using ﬂow
cytometry, ﬂuorescence and transmission electron microscopy (TEM), and inductively coupled plasmon
optical emission spectroscopy (ICP-OES). The effects of nanoparticles on stress and toxicity related genes
were studied in HEp-2 cells. Cytokine response to fGNPs was studied in vitro and in vivo. Biodistribution
of nanoparticles was studied in BALB/c mice using TEM and ICP-OES. VG-21, GNPs and fGNPs had little to
no effect on cell viability. Upon exposure to fGNPs, HEp-2 cells revealed minimal down regulation of
stress response genes. fGNPs displayed higher uptake than GNPs in all cell lines with highest internal-
ization by HEp-2, HeLa and Cos-7 cells, in endocytotic vesicles and nuclei. Cytokine ELISA showed that
mouse J774 cells exposed to fGNPs produced less IL-6 than did GNP-treated macrophage cells, whereas
TNF-a levels were low in both treatment groups. Biodistribution studies in BALB/c mice revealed higher
accumulation of fGNPs than GNPs in the liver and spleen. Histopathological analyses showed that fGNP-
treated mice accumulated 35 ng/mg tissue and 20 ng/mg tissue gold in spleen and liver respectively,
without any adverse effects. Likewise, serum cytokines were low in both GNP- and fGNP-treated mice.
Thus, VG-21-conjugated GNPs have enhanced cellular internalization and are suitable for various
biomedical applications as nano-conjugates.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
To achieve enhanced and targeted delivery of biomolecules,
several delivery vehicles have been developed including nano-
particles. Despite their versatility, metal nanoparticles face chal-
lenges including toxicity, inefﬁciency in translocation into cells and
clearance fromtissues ororgans. To overcomemanyof these barriers,
gold nanoparticles (GNPs) have been employed [1,2]. GNPs, func-
tionalized with nucleic acids, drugs, antibodies, PEG [3], siRNA [3,4]Ltd. This is an open access article uor peptides [5,6], have exhibited low cytotoxicity and excellent bio-
distribution abilities [2]. These functionalized GNPs (fGNPs) are used
for gene transfection and silencing, targeted drug or gene delivery
[5], intracellular detection, bioimaging [7], cancer studies [8,9] and as
biosensors [10]. Among these fGNPs, peptide conjugated GNPs have
been used routinely for enhanced cell penetration efﬁciency.
Most commonly used peptides for conjugation with GNPs are
the cell penetrating peptides (CPPs). CPPs are short peptides with
membrane translocation capability and arewidely used for delivery
of therapeutic molecules, proteins, liposomes, nanoparticles, anti-
sense molecules, siRNA and nucleic acids [11]. CPPs usually trans-
locate through biological membranes via direct penetration,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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[12], clathrin or caveolae-mediated endocytosis [13] or micro-
pinocytosis [14]. Most commonly used CPPs include those from
nuclear localization signals and protein transduction domains of
viruses, amphipathic peptides and arginine rich peptides [12]. The
most commonly used CPP is the commercially available HIV TAT
(protein trans-activator of transcription) peptide [6,15] for delivery
of macromolecules and/or drugs into the nucleus or cytoplasm.
Other CPPs employed for enhanced delivery purposes are human
surfactant protein B (a lung surfactant), orexin (a neuropeptide
hormone) and lactoferricin (a globular glycoprotein) [16], a sec-
ondary amphipathic CPP (named CADY) [17], malittin derived
peptide [4], Rev peptide (from HIV-1 regulatory protein) [18],
CALNNR8 [19] and GC rich peptide with RGD [20] and ﬂock house
virus derived CPP [21].
GNPs functionalized with CPPs translocate to the cytoplasm and
the nucleus [22]. Thus, the rationale behind our study was to
develop a combination of these CPPs and GNPs to provide nano-
vectors for delivery of biomolecules with enhanced cellular up-
take. We have designed a similar peptide, VG-21, from the vesicular
stomatitis virus (VSV) glycoprotein G (VSV-G). VSV is a rhabdovirus
with a non-segmented, negative, single-strand RNA genome,
known to have oncolytic activity against various cancers [23e26].
VSV-G recognizes the receptors on the host cell membrane and
mediates endocytosis of the virion into cells, followed by mem-
brane fusion through structural rearrangement [27]. VSV-G has
been shown to translocate through the stacks of Golgi without
leaving the cisternal lumen and without entering the Golgi vesicles
[28]. Due to its inherent properties of membrane fusion, trans-
location and ability to enhance the transfection efﬁciency, VSV-G
has been used for pseudotyping of the viruses and developing re-
combinant gene transfer vectors, especially in conjunctionwith the
lentiviral vectors [29e32].
For the ﬁrst time, we have designed a CPP (VG-21) from VSV-G
and evaluated its potential for enhanced delivery of GNPs. First, we
functionalized GNPs with VG-21 (fGNPs), followed by character-
ization and evaluation as an intracellular delivery system. We have
also evaluated the efﬁciency of these VG-21 fGNPs in vitro in four
mammalian cell lines (HEp-2, HeLa, Vero and Cos-7) and in vivo in
mice. We hypothesized that VG-21 would enhance the trans-
location efﬁciency of GNPs. In addition, we also evaluated the
interaction of fGNPs with HEp-2 cells by assessing their impact on
stress response genes. Similarly, the impact of fGNPs on cytokine
production was studied in J774 mouse macrophage cells using
ELISA. Finally, we analyzed the translocation efﬁciency and bio-
distribution of these VG-21 fGNPs in comparison to GNPs in mice.
2. Materials and methods
2.1. Peptide characterization
VG-21 peptide derived from VSV-G protein was ﬁrst evaluated for cell pene-
trating efﬁciency. The support vector machine (SVM) based cell penetrating peptide
prediction was performed with CellPPD web server which predicts efﬁcient cell
penetrating peptides [33]. The SVM þ Motif prediction method was selected at an
SVM threshold of 0.1 and a motif e-value of 10. The three dimensional structure of
VG-21 was elucidated using peptide tertiary structure prediction server, Pepstr,
which allows modeling of small peptides (7e25 amino acid residues) [34]. The
Pepstr server then reﬁnes the modeled structure with energy minimization and
molecular dynamic simulations. The structure was validated with VADAR (Volume
Area Dihedral Angle Reporter) web server [35] and analyzed with RasWin and
Molegro molecular viewer. The energy map and surface electrostatics of the peptide
were analyzed using Molegro molecular viewer.
2.2. Nanoparticle functionalization and characterization
Carboxyl-polymer coated spherical GNPs (Nanopartz™, Loveland, CO, USA)
13 nm in size, were functionalized with VG-21 peptide (Bachem Americas Inc., Santa
Clara, CA, USA) using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Sigma
Aldrich, St. Louis, MO, USA) chemistry. Brieﬂy, the GNPs were mixed with peptide(17 mM) and EDC and vortexed for an hour. The peptide concentration was kept
higher than the number of free carboxyl groups on the GNPs. Unbound peptide was
removed by repeated centrifugation at 18000 g for 50 min and the GNPs were
ﬁnally re-suspended in sterile deionized water up to 1 ml. Functionalization was
assessed using UVeVis spectrophotometry (Beckman Coulter spectrophotometer,
Brea, CA, USA) and FTIR spectroscopy. FTIR spectra were collected for GNPs and
fGNPs with an FTIR Nicolet 6700 (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA)
equipped with an attenuated total reﬂectance (ATR) stage, with over 128 scans per
sample with a resolution of 4 cm1; background spectra were automatically
subtracted.
For TEM analysis, nanoparticles were dropped on carbon coated formavar grid
and air dried, prior to observation under the Zeiss EM10 microscope (Carl Zeiss
Meditec, Oberkochen, Germany). DLS measurements (size and zeta potential) of
nanoparticles were done by a Malvern ZS Nano instrument (Malvern Instruments
Westborough, MA, USA).
2.3. Cell viability assay
Human epidermoid type-2 (HEp-2) cells, African green monkey kidney (Vero
and Cos-7) and human cervical cancer (HeLa) cell lines (American Type Culture
Collection, Manassas, VA, USA) were propagated by standard methods using mini-
mum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine, 75 U/ml penicillin, 100 mg/ml kanamycin and 75 mg/ml strepto-
mycin. The cytotoxicity of GNPs, peptides and functionalized GNPs was determined
by MTT (3-(4, 5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) dye
reduction assay using CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT)
kit (Promega, Madison, WI, USA). 96-well plates were seeded at 17,000 cells per well
in MEM containing 10% FBS and grown overnight. Subsequently, nanoparticles at
different concentrations were added to the cells. Cell toxicity was assessed at 24 and
48 h post-incubationwith nanoparticles using the MTT assay per themanufacturer's
instructions. The absorbance was then measured at 570 nm using a microplate
reader (Tecan™ Instruments, San Jose, CA, USA).
2.4. Cellular uptake studies
2.4.1. Fluorescence microscopy
For ﬂuorescence microscopy, FITC conjugated VG-21 peptide was used for
functionalization. Cells were plated in 8 chambered slides at 27,000 cells/ well
concentration. All cell types were incubated with GNPs and fGNPs for 48 h and ﬁxed
in paraformaldehyde-glutaraldehyde, followed by washing with PBS. Nuclei were
stained using DAPI and cell membranes were stained using CellMask™ (Life Tech-
nologies, Carlsbad, CA, USA). The cells were then imaged using the DAPI, FITC and
TRITC channel of the Nikon Ti Eclipse ﬂuorescence microscope (Nikon Inc. Melville,
NY, USA).
2.4.2. Flow cytometry
GNPs functionalized with FITC-conjugated VG-21 were used to study internal-
ization of the nanoparticles by ﬂow cytometry. All cells were seeded at 2  105 cells
per well and incubated overnight at 37 C with 5% CO2, followed by nanoparticle
treatment (1 nM) with an additional incubation for 48 h. These conditions were kept
identical for all other experiments unless stated otherwise. Cells were then disso-
ciated, suspended in MEM with no FBS and analyzed with 20,000 events acquired
using a BD Canto II FACS instrument (BD Biosciences, San Jose, CA, USA) using the
FITC channel. Cells without nanoparticle treatment were used as controls.
2.4.3. Inductively coupled plasmon optical emission spectroscopy (ICP-OES)
Cells were incubated with 1 nM nanoparticles for 48 h, collected and neutralized
in concentrated nitric acid for 5 min on a heating block, followed by ICP-OES analysis
(Perkin Elmer Optima 7300 V HF version, MA, USA). The measurements were per-
formed against gold standard of 1 mg/L.
2.5. Intracellular translocation studies using transmission electron microscopy
(TEM)
Cells were plated and incubated with GNPs and fGNPs for 48 h. Later, the cells
were collected, ﬁxed in glutaraldehyde-paraformaldehyde and osmium tetroxide,
dehydrated through a graded ethanol series to 100% and polymerized in Embed812
resin. Ultrathin sections were collected on copper grids, stained and then imaged
using a Zeiss EM10 TEM microscope.
2.6. Effect of nanoparticles on expression of stress and toxicity related genes in HEp-
2 cells
HEp-2 cells were treated with GNPs and fGNPs for 48 h, followed by RNA
extraction, cDNA synthesis and qPCR for human stress and toxicity genes using
polymerase chain reaction (PCR) array (SA Biosciences, Qiagen, Valencia, CA, USA)
which included 84 stress related genes. The results were analyzed using the SA
Biosciences online PCR array analysis tool.
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HEp-2 and J774 mouse macrophage cells were seeded at 2  105 cells and
3  106 cells per well respectively in 12-well cell culture plate. Cells were then
treated with nanoparticles (1 nM) for 24 and 48 h. LPS (50 ng/ml) was used as the
positive control. Culture supernatants were collected and tested for cytokine levels
for TNF-a and IL-6 using the human and mouse cytokine analysis kit by BD Bio-
sciences per the manufacturer's instructions.
2.8. Biodistribution of GNPs and fGNPs in vivo
Animal experiments were performed according to the National Institutes of
Health (NIH) guidelines for animal use and were approved by Alabama State Uni-
versity's Institutional Animal Care and Use Committee (IACUC). Healthy female 4 to
6 week-old BALB/c mice (Charles River Laboratories Inc, Wilmington, MA, USA) were
housed under standard approved conditions and provided daily with sterile food
and water ad libitum.
The study was conducted with four groups of three mice each. Mice were
injected intravenously with a low dose 63.72 mg (in 200 ml) or high dose 79.65 mg (in
250 ml) of nanoparticles (GNPs or fGNPs), through their tail veins. Control group of
micewere injectedwith sterile PBS. After 2 days, the animals were sacriﬁced through
CO2 asphyxiation. Blood and vital organs including lung, liver, heart, kidney, spleen,
muscles and brainwere collected and stored appropriately until further analyses. The
tissues were used for ICP-OES, TEM analysis and histopathology. For quantiﬁcation of
gold in mice, tissue sections were weighed and digested in concentrated nitric acid
and analyzed. Uptake of gold was measured per mg of tissues. Similarly, mice tissues
with high amounts of gold uptake were chosen for tissue sectioning for TEM and
imaged from several ﬁelds following same protocol as that used for cells.Fig. 1. CPP prediction of VG-21 and three dimensional characterization. (A) sequence and p
green and blue bars represent 20, 15 and 10 amino acid fragments, respectively), (C) 3-D stru
hydrogen acceptor favorable, red color represents electrostatic, yellow color represents hy
trostatic charge, (F) surface hydrophobicity. (For interpretation of the references to color in2.9. Histopathology
Tissues were ﬁxed in formalin and sent to Nationwide Histology reference
laboratory (Spokane, WA, USA). Brieﬂy, tissues were sectioned and stained with
hematoxylin and eosin. The images were takenwith a Canon EOS digital camera on a
Zeiss Axiostar microscope. The histology slides were read by a blinded professional
and scored for pathological adversaries.
2.10. Statistical analysis
All the results were analyzed using GraphPad™ Prism software (La Jolla, CA,
USA) and presented as ±standard error of means. All the results were subjected to
two-way ANOVA and Bonferroni's posttest was applied wherever applicable. The
differences were signiﬁcant at p < 0.0001 (***), p < 0.01 (**) or p < 0.05 (*).
3. Results
3.1. CPP prediction of VG-21 peptide
First, we identiﬁed a 21 amino acids long peptide sequence from
the VSV G-protein and characterized it for cell penetrating efﬁ-
ciency. VG-21 has 4 negatively charged and 1-positively charged
amino acid, with a pI of 4 and was observed to be stable (instability
index 24.11) as per the ProtParam analysis [36]. Taking into
consideration the amino acid composition and sequence arrange-
ment of the peptide (Fig. 1A), its physicochemical properties likerimary structure of VG-21 peptide, (B) SVM score of the CPP predicted motifs (orange,
cture of VG-21, (D) green color represents steric favorable region, blue color represents
drogen donor favorable region associated with VG-21, (E) surface distribution of elec-
this ﬁgure legend, the reader is referred to the web version of this article.)
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amphipathicity, hydrophilicity, net hydrogen, charge, pI and mo-
lecular weight were determined (Supplementary Material S1).
CellPPD predicted VG-21 as a CPP along with all the possible 10, 15
and 20 residue long motifs scanned within this peptide (Fig. 1B).
The three dimensional structure of VG-21 peptide had a knob like
structure, which displayed electrostatic surface distribution,
hydrogen exchange (acceptoredonor favorable) space and hydro-
phobicity associated with the VG-21 peptide (Fig. 1CeF). Upon
careful consideration of its charge, water solubility, structure, CPP
properties and function in silico, the VG-21 was functionalized onto
the GNPs.
3.2. Peptide and GNP conjugation
To conﬁrm functionalization, nanoparticles were characterized
using UVeVis and FTIR spectroscopy. As the size of GNPs and the
length of CPP are inversely related to the extent of stability of GNPs
[19], we selected 13 nm (±2 nm diameter) carboxylated GNPs and
21 amino acid peptide for this study. GNPs were functionalized
with VG-21 using EDC with a molar excess of VG-21 to quench free
carboxyl groups of GNPs. The UVeVis spectra of GNPs shifted fromFig. 2. Characterization of GNPs and fGNPs. UVeVis spectra of GNPs and fGNPs (A), FTIR spe
for fGNPs (B), DLS characterization for GNPs before and after functionalization (C), TEM imag
VG-21 treatment cell viability for HeLa and Cos-7 cells was82% and 88% whereas for HEp-2 ce
GNPs and fGNPs at 1 nM showed 100% viability to Vero, HeLa and Cos-7 cells compared wi520 nm to 517 nm indicating the functionalization of GNPs [37]
(Fig. 2A). FTIR showed peaks between 2000 and 2500 cm1 that
conﬁrmed the conjugation of peptide to GNPs (Fig. 2B). In partic-
ular, appearance of bands at 1217, 1364 and 1732 cm1 and a
considerable reduction of bands located at 2332 and 2361 cm1
were observed. Characteristic differences were observed between
spectra in the 1800e1100 cm1 range, thus afﬁrming successful
conjugation [38].
To assess the stability of the conjugates, zeta potential and
poly-dispersity were measured at 25 C using a dynamic light
scattering (DLS) system, with sterile distilled water as dispersant.
The zeta potential and size measurements also conﬁrmed the
functionalization of GNPs wherein the zeta potential of GNPs
changed from 53.34 mV to 38.36 mV and hydrodynamic
diameter of the GNPs changed from 58.29 nm to 88.40 nm after
functionalization with VG-21 (Fig. 2C). Also, the poly-dispersity
index of the GNPs changed from 0.14 to 0.25. TEM images of GNPs
and VG-21 conjugated GNPs are shown in Fig. 2D. The nano-
particle conjugates were stable for more than a month at 4 C
with minute aggregates which segregated with gentle vortexing,
thus depicting the reversible nature of the nanoparticle clusters
[39].ctra of GNP and fGNPs with additional peaks at 1365 cm1 and 1216.4 cm1 appearing
es of GNPs and fGNPs (D), Cell viability assay of VG-21 (E), GNPs (F), and fGNPs (G). For
lls showed 74% viability as compared to Vero cells with no cytotoxicity (100% viability).
th HEp-2 cells exhibiting 75% and 73% viability for GNPs and fGNPs respectively.
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viability
GNPs and fGNPs were evaluated for their effects on cell viability
on HEp-2, HeLa, Vero and Cos-7 cells (Fig. 2EeG). We did not
observe any severe cytotoxicity of the peptide, GNPs or fGNPs on
any of the cell lines tested by MTT assay. Upon treatment with VG-
21, HeLa and Cos-7 cells had 82% and 88% viability whereas HEp-
2 cells showed 74% viability as compared to Vero cells with no
cytotoxicity (100% viability). GNPs and fGNPs at 1 nM showed no
cytotoxicity to Vero, HeLa and Cos-7 cells compared with HEp-
2 cells exhibiting 75% and 73% viability respectively.3.4. Cellular uptake of VG-21 (FITC) functionalized GNPs
After 48 h of treatment with GNPs and fGNPs, HEp-2, HeLa, Vero
and Cos-7 cells were assessed for nanoparticle uptake using ﬂuo-
rescence microscopy (Fig. 3A). The cells were stained with nuclear
and cell membrane dyes, followed by ﬁxation and imaging using
ﬂuorescence microscopy. Fig. 3A shows internalization of fGNPs by
all cell lines. The qualitative observations of ﬂuorescence micro-
scopy were reinforced by ﬂow cytometry analysis (Fig. 3B). HeLa
and HEp-2 cells expressed higher percentage of FITC-positive cellsFig. 3. Cellular uptake of nanoparticles by HEp-2, HeLa, Vero and Cos-7 cell lines. Uptake of n
ICP-OES (C). In Fig. 3A insets of each fGNP treated cell line images are represented by a di
Asterisks in panel C indicate signiﬁcance differences (***p < 0.001) of fGNP-treated cells a
posttest. (For interpretation of the references to color in this ﬁgure legend, the reader is reat 43.8% and 35.3% respectively, as compared to Vero and Cos-
7 cells at 32.4% and 26.6% respectively.
3.5. VG-21 enhances uptake of GNPs in various cell lines
The amount of GNPs and fGNPs internalized by the cells was
quantiﬁed by ICP-OES. The GNPs internalized was less than that of
fGNPs (Fig. 3C). The GNP uptake for HEp-2, HeLa, Vero and Cos-
7 cells were 0.3 mg/ml, 0.8 mg/ml, 0.2 mg/ml and 0.3 mg/ml,
respectively. The fGNP uptake accounted for 1.4 mg/ml, 1.3 mg/ml,
0.9 mg/ml and 1.3 mg/ml for HEp-2, HeLa, Vero and Cos-7 cells,
respectively. We detected signiﬁcantly higher levels of gold in fGNP
treatment in comparison to the GNP-treatment in all cell lines
especially HEp-2 and Cos-7 cells (***p < 0.001).
3.6. fGNPs and GNPs are localized in endocytotic vesicles and
nucleus
The uptake of GNPs and fGNPs were also conﬁrmed by TEM in
HEp-2, HeLa, Vero and Cos-7 cells (Fig. 4AeD). GNPs and fGNPs
were localized mostly in the endocytotic vesicles. However, some
were localized in the nucleus as well as in other cytoplasmic or-
ganelles. With the exception of a few cells, GNPs were not detected
in large numbers in Cos-7 cells.anoparticles was evaluated by Fluorescence microscopy (A), ﬂow cytometry (B) and by
fferent color (Red for HEp-2, gold for HeLa, purple for Vero and blue for Cos-7 cells).
s compared to GNP-treated cells for all cell lines as determined using the Bonferroni
ferred to the web version of this article.)
Fig. 4. Cellular uptake of GNPs and fGNPs by HEp-2 (A), HeLa (B), Vero (C) and Cos-7 (D) cells. Each panel represents untreated cells, GNP and fGNP treated cells; N-Nucleus, CY-
Cytoplasm. Insets are magniﬁed below each image highlighted with respective colored box (Black for untreated cells, blue for GNP and red for fGNPs). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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genes in HEp-2 cells
We evaluated the effects of GNPs and fGNPs on HEp-2 cells with
respect to stress response genes. The expression of the genes
involved in stress and toxicity was normalized to house-keeping
genes in untreated versus GNP or fGNP treated cells. Stress
response genes were mostly down-regulated in both GNPs andTable 1
Stress response genes expression proﬁle with signiﬁcant changes comparing to untreate
Gene ID Description
Oxidative stress
NM_003900 Sequestosome 1
Hypoxia
NM_001124 Adrenomedullin
NM_000602 Serpin peptidase inhibitor, clade E, member 1
NM_006516 Solute carrier family 2, member 1
Osmotic stress
NM_001628 Aldo-keto reductase family 1, member B1
NM_198098 Aquaporin 1 (Colton blood group)
Cell death
NM_003844 Tumor necrosis factor receptor superfamily, member 10a
NM_006505 Poliovirus receptor
NM_001065 Tumor necrosis factor receptor superfamily, member 1A
Inﬂammatory response
NM_002982 Chemokine (CeC motif) ligand 2
NM_138554 Toll-like receptor 4
*Signiﬁcant at p-value  0.05.fGNPs treated cells (Table 1 and Supplementary Material S2).
However, the down-regulation levels were lower in fGNPs than in
GNPs alone substantiating that masking of GNP surface affects the
behavior of host cells. The genes that were relatively more per-
turbed upon GNP treatment were those involved in the oxidative
stress (peroxiredoxin and sequestosome) and hypoxia (matrix
metallopeptidase 9), osmotic stress (Aldo-keto reductase family 1,
member B1 and Aquaporin 1), genes involved in cell death due tod control group.
GNP fGNP
Fold regulation p-value Fold regulation p-value
5.25 0.03* 3.17 0.06
8.01 0.10 5.43 0.12
9.06 0.13 5.7 0.16
12.17 0.15 6.76 0.18
5.89 0.04* 3.76 0.07
4.97 0.01* 2.3 0.08
11.08 0.06 7.02 0.07
11.12 0.10 6.98 0.12
11.17 0.10 5.15 0.15
7.78 0.16 3.74 0.19
8.16 0.01* 5.63 0.01*
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and TLR-4) and a heat shock protein called activating transcription
factor 4 (tax-responsive enhancer element B67). As compared to
GNP treated cells, fGNP treated cells suffered less deviation from
the cellular gene expression level. Genes with down-regulation in
expression included those associated with apoptosis (myeloid cell
leukemia sequence 1 (BCL2-related), inﬂammatory response (IFN
a), autophagy (ATG12 autophagy related 12 homolog (Saccharo-
myces cerevisiae)), cell cycle checkpoint/arrest (CHK1 checkpoint
homolog (Schizosaccharomyces pombe)), MRE11 meiotic recombi-
nation 11 homolog A (S. cerevisiae), growth arrest and DNA-
damage-inducible, alpha and heat shock 70 kDa protein 4. How-
ever, fewgeneswere down-regulated both in GNP and fGNP treated
cells. These included hypoxia (vascular endothelial growth factor
A), apoptosis [Caspase 1, apoptosis-related cysteine peptidase
(interleukin 1, beta, convertase)], inﬂammatory response (TLR-4)
and a heat shock protein activating transcription factor 4 (tax-
responsive enhancer element B67).
3.8. Cytokine production analysis
GNPs have been reported to cause changes in the expression of
cytokines including IL-6, IL-1b and TNF-a [40]. IL-6 is important for
Th1/Th2 differentiation as it acts both as a pro- and anti-
inﬂammatory cytokine. Tumor necrosis factor (TNF-a) is a cyto-
kine chieﬂy produced by activated macrophages and has anFig. 5. Cytokine production analysis. Cytokine analysis for IL-6 (A) and TNF (B) in J774 cells
p < 0.01 (**) or p < 0.05 (*) as determined using the Bonferroni posttest.important role in the regulation of immune cells, especially for
phagocytosis of pathogen and in systematic inﬂammation. The ef-
fect of our GNPs and fGNPs were investigated for the production of
IL-6 (Fig. 5A) and TNF-a (Fig. 5B) in J774 (murine macrophage) cell
line. ELISA results show that IL-6 production level was low at
123 pg/ml for fGNP-treated J774 cells as compared to GNP treat-
ment (225 pg/ml) with further decrease in its production level in
both treatment groups after 48 h. TNF-a production did not show
any signiﬁcant difference upon treatment with the nanoparticles
for 24 or 48 h.
Similarly, serum cytokine levels were also measured for IL-6
(Fig. 5C) and TNF-a (Fig. 5D), with no signiﬁcant differences
observed.
3.9. Biodistribution of nanoparticles in various organs
We also studied the biodistribution efﬁciency of GNPs and
fGNPs in lung, liver, heart, kidney, spleen, brain andmuscle of mice,
post intravenous injection with nanoparticles. Groups of mice
received low (63.72 mg/mouse) or high dose (79.65 mg/mouse) of
GNPs or fGNPs, respectively. Control groups were injected with PBS
or VG-21. The highest amount of gold was detected in spleens from
GNP and fGNP groups at both low and high dose (Fig. 6A and B). The
amount of gold for GNP groups was 26 ng at low dose and 20 ng at
higher dose per mg of spleen tissue. However, the amount of gold in
functionalized groupwas 20 ng and 35 ng permg of spleen tissue atand serum IL-6 (C) and serum TNF (D). Signiﬁcance were established at p < 0.001 (***),
Fig. 6. Uptake and biodistribution of gold nanoparticles in mice. Biodistribution of GNPs and fGNPs in mice tissues, assessed by ICP-OES at low dose (63.72 mg/mouse) (A) and high
dose (79.65 mg/mouse) (B) The uptake of fGNPs was signiﬁcantly higher than the GNPs in all organs. Signiﬁcance was established determined using the Bonferroni posttest
(***p<0.001). Uptake of gold nanoparticles by liver and spleen via endocytosis (C) Histopathology analysis of effect of gold nanoparticles on mice tissues (D).
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liver was similar in both GNP and fGNP groups at low dose and was
found to be 12.5 ng/mg; however, when higher concentration was
used, this accumulation was reduced to 6 ng/mg in GNP group
compared to 20 ng/mg in fGNP group.
Lung tissues did not show any signiﬁcant increase in gold
accumulation at both doses. The amount of gold for GNP group
remained similar at 11.41 and 11.40 ng/mg tissue at low and high
doses, respectively. The accumulation of fGNPs in lung at low dose
was 6.27 ng/mg tissue and 6.64 ng/mg tissue at high dose. Inter-
estingly at low concentration of nanoparticles, GNP group had
signiﬁcantly higher amount of gold compared to fGNP group (p-
value <0.001) in heart, with GNP group accumulating 15.8 ng gold
as compared to fGNP with 7.4 ng/mg tissue. The heart in fGNP
group had higher gold (11.1 ng/mg tissue) compared to GNP group
(9.6 ng/mg tissue) at high dose. fGNPs showed rapid clearance from
kidneys at both doses and accumulated only 3.7 ng and 5.3 ng per
mg of tissue. This accumulation in kidneywas higher for GNP group
at 7.3 ng and 7.9 ng per mg tissue.
The other tissues studied were brain and muscle which accu-
mulated very low amounts of gold. Brain tissues had 1 ng/mg tissue
in all four groups. Muscle tissues had 1 ng/mg gold in both groups
at high dose, whereas at low dose, GNP group accumulated 3.4 ng
versus 2 ng in fGNP group per mg tissue.3.10. fGNPs localize into endocytotic vesicles in vivo
To conﬁrm the uptake of GNPs and fGNPs by mice tissues and to
determine their localization, liver and spleen tissues from mice
administered with nanoparticles were ultra-sectioned, stained and
imaged using TEM (Fig. 6C). The fGNPs both in spleen and liver
showed higher uptake in endocytotic vesicles (Fig. 6C inset).3.11. Histopathology
For histopathology, mice tissues from lung, liver, heart, kidney,
spleen, brain and skeletal muscle were collected, ﬁxed and
sectioned, followed by hematoxylin and eosin staining (Fig. 6 D).
The range of changes and the scoring indicate absence of inﬂam-
matory, infectious, signiﬁcant degenerative and necrotizing lesions
in all organs in all groups examined. In the absence of signiﬁcant
lesions quantitative scoring was not meaningful or desirable.
Overall, the changes in all the tissues were within the normal his-
tologic limits and were deemed to be 0 on a scale of 0e5 grading
where 5 is considered the most abnormal and 0 the most normal.
Our results contradict a previous report inwhich GNPs were shown
to cause histological alterations in rat liver [41].
3.12. Effects of GNPs on blood cell counts
Blood samples collected from all groups of mice were assayed
for blood cell counts. None of the samples revealed any signiﬁcant
deviation from the normal cell counts, indicating that the nano-
particles used in the study do not affect blood cell counts
(Supplementary Fig. S3).
4. Discussion
Efﬁcient intracellular delivery of nanoconjugates has always
been a critical issue mainly due to cell membrane barriers and
clearance from the body. Therefore, engineering nanoparticles that
can enter various cell types and reduce circulation time can
circumvent these challenges. Peptide functionalized GNPs have
widely been studied for the delivery of drug(s), nucleic acids and
siRNAs [2,36].
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GNPs, for uptake by different cell lines and biodistribution in BALB/
c mice via intravenous injection. The VG-21 functionalized GNPs
were characterized using zeta potential, UVevis and FTIR spec-
troscopy and were evaluated as a potential nano-delivery vehicle.
Cell viability has been related to the shape, size, surface coatings on
the nanoparticles as well as the type of cell being studied [42]. Thus,
VG-21 makes our fGNPs minimal to non-cytotoxic to the cell lines
tested, making them suitable as delivery vehicles for both in vitro
and in vivo studies. Furthermore, the nanoparticle diameter and
surface coverage of the peptide affects both the internalization of
nanoparticles and sub-cellular target (nucleus or cytoplasm) [19].
Nanoparticle uptake is also related to the extent of aggregation,
expression of target receptors, endocytosis mechanism and cell
phenotypes [39]. VG-21 functionalized GNPs showed less aggre-
gation thereby enabling their long term stability both in vitro and
in vivo. The ﬂow cytometric analyses clearly showed that nano-
particles were differentially internalized by all cell types and in the
order of HeLa > HEp-2 > Vero > Cos-7. This suggests that HeLa and
HEp-2 were preferred over other cell lines. Previously, aggregation
of transferrin-coated GNPs was reported to decrease the uptake by
HeLa cells via receptor-mediated endocytosis. However, on the
contrary, we found HeLa cells to uptake fGNPs easily, thus fortifying
our hypothesis that VG-21 functionalization enhances GNP uptake.
We believe that the uptake of fGNPs is governed by the cells' ability
to either allow or block the entry of fGNPs suggesting receptor
mediated endocytosis.
Moreover, the cationic polymer(s) or coating on GNPs facilitates
entry into the cells due to negative charges on the membrane.
Cationic, arginine-rich CPPs were reported to use direct penetration
mechanism predominantly [43]. However, our ﬁndings are con-
tradictory as VG-21 is not an arginine rich peptide as opposed to
other CPPs. Moreover, the slight negative charge of VG-21 indicates
that the entry mechanism involvedmay not be electrostatic instead
it could be either direct penetration, non-speciﬁc or receptor
mediated endocytosis. Our hypothesis is supported by previous
reports that negatively charged smaller GNPs can also be inter-
nalized efﬁciently [44] either via endocytosis [45] or through
phagocytosis [46]. Our results are in accordance with previous
studies in that the nanoparticles were located mostly in the
endocytotic vesicles [44] and some in the nuclei [47], as shown by
ﬂuorescence microscopy and TEM. In spite using the same ﬁxation
protocols, cells exhibited differential uptake behavior possibly due
to diffusion of nanoparticles through cell membrane, ruling out the
nuclear uptake as an artifact [22].
While evaluating the effectiveness of a potential delivery vector
for siRNA, drug(s) or any other macromolecule, it becomes imper-
ative to study the gene expression proﬁles of the host cells. The
changes in our fGNPs treated HEp-2 cells were reduced as
compared to that of GNP treated cells. Also, the extent of alteration
was mostly in stress response genes which have previously been
reported to show altered gene expression upon nanoparticle
treatment [48]. From the expression proﬁles of both GNP and fGNP
treated cells, it is evident that bare GNPs exert some stress on the
cells that is signiﬁcantly reduced upon conjugation of VG-21. These
results are similar to several reports of changes in gene expression
inmice [48,49] and human peripheral bloodmononuclear cells [50]
upon GNP treatment.
We also studied the effect of nanoparticles treatment on IL-6
and TNF-a production. Our results indicate that GNPs and fGNPs
do not induce severe cytokine production and are in accordance
with a previous study, in which GNPs conjugated to DNA were
shown to have limited immune activation response [51]. Cytokine
production has been associated with the shape as well as the type
of conjugate rendered on the GNP surface [52]. It has beenpreviously reported that GNP-peptide conjugates induce expres-
sion of TLR-4 and IL-1bmore than the peptide alone and that these
conjugated GNPs could possibly act as adjuvants with advantages
as easier design, low toxicity and effective biodistribution [40].
Based on these results VG-21 functionalized GNPs can be conju-
gated to adjuvants and immunomodulators of choice, without their
own interference in the process. Thus, these nanoparticles could be
suitable for targeted delivery purposes with the possibility of being
employed with activators of the immune system.
The biodistribution studies in mice revealed that GNPs and
fGNPs were mostly located in liver and spleen. Our results are
attributed to the fact that the small sized nanoparticles (13 nm ± 2)
are usually uptaken by reticulo-endothelial organs (RES), liver and
spleen [7]. However, some studies report that nanoparticles injec-
ted intravenously accumulate in liver and spleen for long durations,
regardless of their size, shape and material [48]. The higher accu-
mulation of gold in spleen may also be attributed to the higher
ﬁltering efﬁcacy of the spleen [7]. Larger nanoparticles have been
shown to have slower clearance from blood and higher uptake in
liver and spleen, because of the size match of smaller nanoparticles
with those of liver fresternae and endothelial walls of liver [7]. The
possible explanation of uptake by liver is that the spleen is
temporarily saturated upon intravenous injection, allowing the
uptake by liver. The higher uptake is also attributed to the presence
of higher number of phagocytic cells and capillary beds in liver [7].
It has been also reported that increasing the duration of nano-
particle treatment increases the amount of gold increased in kid-
neys. We observed similar results, the highest amount of gold per
mg of tissue was observed in spleens, followed by liver, lung, heart,
and kidney. GNP group mice retained gold in most of the organs
leading to slower clearance from the organs. The retention of GNPs
could be due to the fact that serum proteins adsorb onto the surface
of bare GNPs, thereby modifying their surface properties [37], in
turn affecting uptake by tissues. It also indicates that fGNPs were
cleared from circulation by translocating, accumulating and ulti-
mately removed out of the body. As expected, in case of mice tis-
sues, the amount of gold was higher in the fGNP group as compared
to GNP group, conﬁrming our hypothesis that the VG-21 helps in
the internalization of GNPs in otherwise difﬁcult to penetrate tis-
sues. Thus, in summary, VG-21 functionalization helps not only in
higher uptake of fGNPs but also in faster clearance from the tissues.
In spite of higher uptake by RES organs, the liver and spleen,
histopathological analysis showed no signs of tissue damage and
had similar morphologies to those of controls, substantiating the
suitability of VG-21 fGNPs for use as a targeted drug or molecule
delivery vehicle.
5. Conclusion
We have reported for the ﬁrst time the application of VG-21
peptide for intracellular delivery of GNPs. VG-21 could serve as a
new cell penetrating peptide for various cell lines as demonstrated
in our in vitro and in vivo studies. We successfully developed a
functionalized gold nanoparticle system for efﬁcient delivery into
the cytoplasm. Also, these fGNPs did not render any cytotoxic ef-
fects as opposed to other studies, indicating that the peptide
conjugation to the GNPs may also help eliminate the adverse
cytotoxic and molecular effects on the host cells. From our in vivo
results it is very clear that the fGNPs can successfully enter various
tissues and be cleared from the animal circulatory system without
any adverse effects to the organs. This paves the way for using VG-
21 functionalized GNPs for extended biomedical applications such
as delivery of drugs, proteins, siRNA, ﬂuorophores and other mol-
ecules. The discrimination in taking up the fGNPs is an attribute of
cell surface morphology and the ability of VG-21 to recognize
P.M. Tiwari et al. / Biomaterials 35 (2014) 9484e9494 9493cellular targets present on these cells which need to be identiﬁed.
These targets might help in designing cell speciﬁc delivery of our
fGNPs to target cells. Also, it is possible to conjugate cell speciﬁc
markers and ﬂuorescent dyes along with VG-21-fGNPs for targeted
and enhanced intracellular delivery, apt for bioimaging, diagnostic
and therapeutic applications. Thus, VG-21 helps subtle the alter-
ations in gene expression and might be useful as a delivery system.
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